In the following years, new antihyperglycemic agents were gradually introduced in clinical practice, including the dipeptidyl-peptidase 4 (DPP-4) inhibitors, which have a safe profile in terms of hypoglycemia. This evidence concerns the gene DPP4 and Hypoglycemia.